StimLabs enrolls first patient in Revita trial for diabetic foot ulcers

StimLabs, a provider of regenerative technologies and products, has enrolled first patient in its trial designed to assess the safety and efficacy of Revita human placental graft in diabetic foot ulcers (DFUs) … Revita is said to be the first amniotic placental membrane allograft to capture the complete intact membrane in a shelf-stable format … The multi-center randomized, comparative and controlled trial will assess the efficacy of Revita full thickness placental allograft in improving wound closure rates and mean closure time in DFUs compared against current standards of wound care treatment … StimLabs is carrying out the trial at primary institutions/centers in the US. The trial includes patients who suffer from type 1 or 2 diabetes … read more